Clinical Trials
51 trialsCombined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
National Cancer Institute (NCI)
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
National Institutes of Health Clinical Center (CC)
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
National Institutes of Health Clinical Center (CC)
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
S1310
National Cancer Institute (NCI)
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
National Institutes of Health Clinical Center (CC)
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
National Cancer Institute (NCI)
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
National Cancer Institute (NCI)
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
National Institutes of Health Clinical Center (CC)
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
National Cancer Institute (NCI)
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
National Cancer Institute (NCI)
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
National Cancer Institute (NCI)
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
National Cancer Institute (NCI)
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
IMC-A12 in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
National Cancer Institute (NCI)
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
T900607 in Treating Patients With Unresectable Liver Cancer
National Cancer Institute (NCI)
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Oxaliplatin in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
National Cancer Institute (NCI)
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
National Cancer Institute (NCI)
Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
National Cancer Institute (NCI)
Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
National Cancer Institute (NCI)
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)